| Released | Contributor | Author | Title | Pages | Price |
| 10-Feb-2010 | New Constructs, LLC |
N/A
| THLD: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for THLD | 13 |
$25 |
| 6-Feb-2010 | Pechala's Reports | Frantisek Pechala | THRESHOLD PHARMACEUTICALS INC (THLD=US) 12-months forecast | 1 |
$15 |
| 6-Feb-2010 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 6-Feb-2010 | Standard & Poor's Quantitative Report |
N/A
| Threshold Pharmaceuticals | 6 |
$25 |
| 5-Feb-2010 | Pechala's Reports | Lubomir Pechala | THRESHOLD PHARMACEUTICALS INC (THLD=US) 2-weeks forecast | 1 |
$10 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Value Graph: THRESHOLD PHARMA -- THLD | 1 |
$4 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ADLS , CXM , INHX , THLD -- DRUGS | 3 |
$4 |
| 2-Feb-2010 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Threshold Pharmaceuticals, Inc. | 40 |
$65 |
| 2-Feb-2010 | EconomicInvestor |
N/A
| "The Economy Matters" Report for THLD: the economy's impact on THLD's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
0.34% Nasdaq 
Research Reports
